Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bumetanide and furosemide.

D C Brater, P Chennavasin, B Day

    Clinical Pharmacology and Therapeutics
    |August 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Effect of Prolonged Pressure on Hemodynamics of Sacral Tissues Assessed by Diffuse Optical Imaging: A Pilot Study.

    Advances in experimental medicine and biology·2021
    Same author

    Tests of General Relativity with GW170817.

    Physical review letters·2019
    Same author

    Constraining the p-Mode-g-Mode Tidal Instability with GW170817.

    Physical review letters·2019
    Same author

    Search for Subsolar-Mass Ultracompact Binaries in Advanced LIGO's First Observing Run.

    Physical review letters·2018
    Same author

    GW170817: Measurements of Neutron Star Radii and Equation of State.

    Physical review letters·2018
    Same author

    Search for Tensor, Vector, and Scalar Polarizations in the Stochastic Gravitational-Wave Background.

    Physical review letters·2018
    Same journal

    Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.

    Clinical pharmacology and therapeutics·2026
    See all related articles

    Bumetanide shows 200% higher bioavailability and significantly greater potency than furosemide, with both drugs rapidly absorbed and excreted unchanged in urine. This study compares their pharmacokinetic and pharmacodynamic properties in healthy subjects.

    Area of Science:

    • Pharmacology
    • Nephrology
    • Clinical Therapeutics

    Background:

    • Furosemide and bumetanide are loop diuretics used to treat fluid overload.
    • Understanding their comparative pharmacokinetic and pharmacodynamic profiles is crucial for optimizing patient care.

    Purpose of the Study:

    • To compare the response to and handling of furosemide and bumetanide in normal subjects.
    • To determine the bioavailability, excretion, and dose-response relationships of both diuretics.

    Main Methods:

    • Administered oral doses of furosemide (20-80 mg) and bumetanide (0.5-2 mg).
    • Administered intravenous doses of bumetanide (0.5-1 mg).
    • Measured urinary excretion of unchanged drugs and sodium to assess pharmacokinetics and pharmacodynamics.

    Related Experiment Videos

    Main Results:

    • Both drugs were rapidly absorbed, with peak urinary excretion at a median of 75 minutes.
    • Approximately 30% of oral doses were excreted unchanged, with no dose-dependent elimination.
    • Bumetanide exhibited 80% bioavailability, compared to approximately 40% for furosemide.
    • Bumetanide demonstrated significantly greater potency, with a lower dose inducing half-maximal sodium excretion response.

    Conclusions:

    • Bumetanide possesses substantially higher bioavailability and greater potency than furosemide.
    • These differences in pharmacokinetic and pharmacodynamic properties distinguish bumetanide from furosemide, potentially influencing their clinical applications.